GRK5基因多态性通过损害PAR1脱敏增强血栓风险
GG血小板GRK5蛋白较AA对照低90%,导致对凝血酶和PAR1激动剂反应增强而非PAR4,PAR1内化减少、信号增强。在微流控静脉剪切和鼠动脉血栓模型中GG血小板聚集和血栓形成增加,可被vorapaxar逆转。
要点
- GRK5 GG基因型血小板GRK5蛋白较AA低90%,对凝血酶和PAR1激动剂反应增强。
- GG血小板PAR1内化减少致信号增强,PAR1抑制可逆转其聚集增加。
- GRK5 GG基因型通过损害PAR1脱敏增加血栓潜力,提示PAR1靶向可能获益。
核心结论
- GRK5 GG基因型通过损害PAR1脱敏增强血栓潜力,首次实验证据连接该变异与血栓风险。
研究设计与样本
- 研究鉴定3名GRK5 GG个体,比较GG与AA血小板GRK5蛋白水平及功能反应。
- 采用GRK5-/- iPSC来源巨核细胞、Grk5缺陷小鼠血小板和GRK5抑制剂处理AA血小板验证。
- 在内皮化微流控系统静脉剪切及人血小板输注鼠动脉血栓模型中评估血栓形成。
主要发现
- GG血小板GRK5蛋白水平较AA对照低90%。
- GG血小板对凝血酶和PAR1激动剂反应增强,对PAR4激动剂无增强。
- GG血小板PAR1内化减少,PAR1信号增强。
- 静脉剪切下GG血小板聚集增加,vorapaxar抑制PAR1可逆转。
- 鼠动脉血栓模型中GG血小板体内血栓形成增强。
临床怎么用
- GRK5 GG基因型个体血栓风险增加,PAR1抑制(如vorapaxar)可能逆转其血小板聚集增强。
- 该变异可能作为血栓风险分层和PAR1靶向治疗选择的潜在标志。
局限性
- 仅鉴定3名GG个体,样本量小。
- 机制验证主要依赖体外和动物模型,需进一步临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inherited genetic variants that modulate platelet function contribute significantly to thrombotic disorders, yet their mechanisms and clinical implications remain underexplored. Two genome-wide association studies identified an A→G variant (rs10886430) in the first intron of G protein-coupled receptor kinase 5 (GRK5), found in homozygosity in ∼5 million Americans. The homozygous GRK5 GG genotype is associated with an increased risk of stroke and venous thromboembolism, but the mechanistic link between this variant and thrombotic risk has remained unclear. To investigate this, we identified 3 GG individuals. GRK5 protein levels in GG platelets were 90% lower than in AA controls. The significant reduction in GRK5 levels in GG platelets led to elevated platelet responsiveness to thrombin and a protease-activated receptor 1 (PAR1) agonist but not a PAR4 agonist. These findings were corroborated in GRK5-/- induced pluripotent stem cell-derived megakaryocytes, transgenic Grk5-deficient murine platelets, and AA platelets exposed to a GRK5 inhibitor. We demonstrated that PAR1 internalization was reduced in GG platelets, leading to enhanced PAR1 signaling. Under venous shear in an endothelialized microfluidic system, GG platelets exhibited increased accumulation, which was reversed by PAR1 inhibition with vorapaxar. In an arterial murine thrombosis model following human platelet infusion, GG platelets also showed enhanced thrombus formation in vivo. This study provides, to our knowledge, the first experimental evidence directly linking a highly prevalent human GRK5 variant to defective PAR1 regulation and increased thrombotic risk. Together, these findings establish that the GRK5 GG genotype confers increased thrombotic potential through impaired PAR1 desensitization, providing mechanistic insight that connects human genetics, thrombin receptor signaling, and thrombotic disease.
引用
- Yarman Y, Zhao X, Ahn H, et al. Understanding how a highly prevalent GRK5 polymorphism affects platelets and enhances thrombotic risk. Blood. 2026. PMID: 41557909. doi:10.1182/blood.2025030223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。